ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-10-26

In 299 patients with mismatch repair-deficient advanced or recurrent endometrial cancer, first-line pembrolizumab beat carboplatin-paclitaxel on progression-free survival (median 38·2 vs 8·4 months; HR 0·57); overall survival not significant at interim analysis.

RCTn = 299
Slomovitz et al. First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
Oncology · J Clin Oncol · 2026-09-09

Secondary analysis of a phase II trial of preoperative radiotherapy with or without pembrolizumab in 106 patients with localised soft tissue sarcoma: personalised ctDNA was found in 85% at baseline and levels independently predicted survival.

Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
Oncology · Lancet Oncol · 2026-09-07

In 1367 women with advanced BRCA non-mutated ovarian cancer, pembrolizumab-chemotherapy then pembrolizumab-olaparib maintenance improved progression-free survival vs chemotherapy (ITT HR 0·68 interim, 0·71 final); pembrolizumab alone did not (CPS≥10 HR 0·95).

RCTn = 1,367
Vergote et al. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.